Compare NEPH & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEPH | INKT |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.0M | 51.7M |
| IPO Year | 2004 | 2021 |
| Metric | NEPH | INKT |
|---|---|---|
| Price | $5.02 | $12.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 74.6K | 19.7K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $17,930,000.00 | N/A |
| Revenue This Year | $33.32 | N/A |
| Revenue Next Year | $12.27 | N/A |
| P/E Ratio | $36.15 | ★ N/A |
| Revenue Growth | ★ 32.36 | N/A |
| 52 Week Low | $1.39 | $4.56 |
| 52 Week High | $6.42 | $76.00 |
| Indicator | NEPH | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 51.40 |
| Support Level | $4.83 | $11.48 |
| Resistance Level | $5.97 | $13.34 |
| Average True Range (ATR) | 0.63 | 0.84 |
| MACD | -0.03 | 0.27 |
| Stochastic Oscillator | 28.93 | 67.49 |
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.